Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product
EMA accepted companies' MAA...
8 July 2013 | By Boehringer Ingelheim
EMA accepted companies' MAA...
List view / Grid view
EMA accepted companies' MAA...
8 July 2013 | By Boehringer Ingelheim
EMA accepted companies' MAA...
Announces it will begin remainder of pre-planned clinical trials for…
7 January 2013 | By Boehringer Ingelheim
Announces it will begin remainder of pre-planned clinical trials for LY2605541...
Phase II trial used ambulatory blood pressure monitoring to evaluate…
22 May 2012 | By Eli Lilly and Company
Phase II trial used ambulatory blood pressure monitoring to evaluate blood pressure and heart rate for dulaglutide...